Men with recurrent prostate cancer following surgery or radiation therapy may now have a new chance to live longer. A massive ...

Sapanisertib combined with weekly paclitaxel improved PFS in platinum-resistant ovarian cancer, reducing the risk of death by 34% compared to paclitaxel alone. The combination therapy was generally ...

A large trial shows calcium supplements do not raise dementia risk in older women. Discover the impact—keep reading for ...

The addition of Tecentriq to BCG therapy did not significantly improve outcomes for patients with non–muscle-invasive bladder ...

Capivasertib addition to standard therapy extended rPFS by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate ...

In the intent-to-treat population, the median progression-free survival (PFS) was 8.77 months with giredestrant plus Afinitor ...

Atezolizumab shows no significant benefit over BCG alone in treating high-risk non-muscle invasive bladder cancer, according to the ALBAN trial results.

Postdiagnosis smoking cessation was linked to significantly longer overall survival among cancer patients across all stages, ...

Investigators have developed a prognostic model that may identify which patients with MIBC are suitable for bladder-preserving chemoradiation.

Discusses 2-Year Phase II Data and AI Immunology Platform in High-Risk Melanoma October 22, 2025 10:30 AM EDTCompany ...

On-treatment PSA and disease burden should be considered together for prognostication. Achieving PSA ≤0.2 ng/mL within 6–12 weeks strongly predicts favorable long-term survival. Metastatic volume and ...